Big data and cancer

Laura Pedulli | | Health Exec | Digital Transformation

If big data is so useful in medicine, why isn’t it more widespread? The “stubborn culture of medicine” and slow technological adoption are some of the culprits, according to U.S. News & World Report.

But while progress is slow, patient demands and pressures from the Affordable Care Act may mean that the tipping point has come.

Read more below:

Can Big Data Cure Cancer?

Laura Pedulli

Related Content

2024 in AI weirdness: ‘Insane’ ChatGPT and mutant rat genitals were only the beginning
10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.